Clinical significance of long non-coding RNA SChLAP1 expression in prostate cancer tissue and its relationship with prognosis
-
摘要:目的 探讨前列腺癌组织中长链非编码RNA（LncRNA）SChLAP1表达水平与临床病理参数及临床预后的关系。方法 采用实时荧光定量聚合酶链反应（qRT-PCR）测定前列腺癌组织、癌旁正常组织以及良性前列腺增生组织中LncRNA SChLAP1的表达水平；分析LncRNA SChLAP1表达水平与临床病理参数的关系；采用Kaplan-Meier生存曲线分析前列腺癌患者总生存期（OS）和无病生存期（DFS）；采用Cox风险回归模型分析前列腺癌患者临床预后的危险因素。结果 前列腺癌组织中Lnc RNA SChLAP1的表达水平高于癌旁正常组织、良性前列腺增生组织，差异有统计学意义（P < 0.01）。前列腺癌患者的1、2、3年无疾病生存率分别为84.69%、65.31%和46.94%，总生存率分别为89.80%、76.53%和58.16%；前列腺癌组织中LncRNA SChLAP1表达水平与患者肿瘤分期、肿瘤分化程度、淋巴结转移和Gleason评分有关（P < 0.05），与患者的年龄和肿瘤大小无关（P>0.05）。LncRNA SChLAP1高表达患者的FDS和OS低于LncRNA SChLAP1低表达患者，差异有统计学意义（P < 0.05）。肿瘤分期、肿瘤分化程度、淋巴结转移、Gleason评分和LncRNA SChLAP1表达水平均为前列腺癌患者DFS和OS的影响因素（P < 0.05）。结论 LncRNA SChLAP1在前列腺癌组织中呈高表达，并且可能与前列腺癌的发生发展有关，可作为前列腺癌临床预后的评价指标。Abstract:Objective To investigate the relationship of the expression level of long non-coding RNA (LncRNA) SChLAP1 with clinicopathological parameters and clinical prognosis in prostate cancer tissue.Methods The expression levels of LncRNA SChLAP1 in prostate cancer tissues, normal adjacent tissues and benign prostatic hyperplasia tissues were determined by quantitative real-time polymerase chain reaction (qRT-PCR); the relationships between the expression levels of LncRNA SChLAP1 and clinicopathological parameters were analyzed; Kaplan-Meier survival curve was used to analyze the overall survival (OS) and disease-free survival (DFS); Cox risk regression model was used to analyze the risk factors for clinical prognosis of prostate cancer patients.Results Expression level of LncRNA SChLAP1 in prostate cancer tissue was significantly higher than that in adjacent normal tissue and benign prostatic hyperplasia tissue (P < 0.01). The 1-year, 2-year and 3-year disease-free survival rates were 84.69%, 65.31% and 46.94%, respectively, and the overall survival rates were 89.80%, 76.53% and 58.16%, respectively. The expression level of LncRNA SChLAP1 in prostate cancer tissues was correlated with tumor stage, tumor differentiation, lymph node metastasis and Gleason score (P < 0.05), and was not correlated with the patient's age or tumor size (P>0.05). FDS and OS in patients with high expression of LncRNA S ChLAP1 were significantly lower than those in patients with low expression of LncRNA SChLAP1 (P < 0.05). The tumor stage, tumor differentiation, lymph node metastasis, Gleason score and LncRNA SChLAP1 expression were all influential factors of DFS and OS in prostate cancer patients (P < 0.05).Conclusion LncRNA SChLAP1 is highly expressed in prostate cancer tissues and may be related to the occurrence and development of prostate cancer, which can be used as an evaluation index of clinical prognosis of prostate cancer.
-
-
![]()
图 2 不同LncRNA SChLAP1表达水平前列腺癌患者的DFS和OS分析
A: 不同LncRNA SChLAP1表达水平前列腺癌患者的DFS; B: 不同LncRNA SChLAP1表达水平前列腺癌患者的OS。
表 1 qRT-PCR引物序列
引物 序列 SChLAP1 F: 5′-CGGAGAGGATGGGCTCTGGCATT-3′ R: 5′-AGGGACCCTTCAGGGTGGCTG -3′ GAPDH F: 5′-GGTGAAGGTCGGAGTCAA CG-3′ R: 5′-CCATGTAGTTGAGGTCAATGAAG-3′ 
下载: 导出CSV
表 2 LncRNA SChLAP1表达水平与前列腺癌临床病理学参数的关系(x±s)
临床资料 n LncRNA SChLAP1 t P 年龄 1.195 0.238 < 60岁 50 3.63±0.82 ≥60岁 48 3.44±0.75 肿瘤大小 1.328 0.190 < 3 cm 48 3.65±0.73 ≥3 cm 50 3.44±0.83 肿瘤分期 5.724 < 0.001 T1~2期 50 3.15±0.60 T3~4期 48 3.94±0.76 肿瘤分化程度 7.481 < 0.001 低分化 24 4.18±0.90 中高分化 74 3.08±0.51 淋巴结转移 7.479 < 0.001 是 34 4.11±0.50 否 54 3.24±0.55 Gleason评分 7.288 < 0.001 < 7分 69 3.24±0.51 ≥7分 29 4.26±0.86
下载: 导出CSV
表 3 前列腺癌患者DFS影响因素的Cox回归分析
因素 β SE Wald χ2 HR 95%CI P 年龄 0.361 0.392 0.752 1.272 0.952~1.847 0.172 肿瘤大小 0.452 0.415 0.549 1.186 0.612~1.526 0.284 肿瘤分期 1.047 0.327 6.746 2.217 1.549~3.265 0.012 肿瘤分化程度 1.094 0.295 5.347 1.762 1.028~2.347 0.015 淋巴结转移 1.281 0.329 3.541 2.175 1.365~2.985 0.037 Gleason评分 0.825 0.221 9.467 2.784 1.786~3.567 0.005 LncRNA SChLAP1表达水平 1.123 0.284 6.984 1.925 1.426~2.754 0.009
下载: 导出CSV
表 4 前列腺癌患者OS影响因素的Cox回归分析
因素 β SE Wald χ2 HR 95%CI P 年龄 0.364 0.412 0.826 1.382 0.895~1.627 0.146 肿瘤大小 0.481 0.387 0.653 1.254 0.743~1.825 0.112 肿瘤分期 1.095 0.319 7.432 2.430 1.762~3.486 0.009 肿瘤分化程度 1.135 0.274 6.164 1.864 1.117~2.653 0.010 淋巴结转移 1.325 0.346 4.173 2.361 1.475~3.128 0.017 Gleason评分 0.875 0.212 11.256 2.984 1.985~3.976 0.001 LncRNA SChLAP1表达水平 1.027 0.215 8.471 2.145 1.576~2.965 0.003
下载: 导出CSV
-
[1] LIU J, MAO R F, REN G P, et al. Whole exome sequencing identifies putative predictors of recurrent prostate cancer with high accuracy[J]. OMICS, 2019, 23(8): 380-388. doi: 10.1089/omi.2019.0044
[2] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
[3] CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[4] 王之泽, 张宇聪, 丁北辰, 等. 雄激素受体剪接突变体7和雄激素受体表达量的比值在预测前列腺癌内分泌治疗预后中的作用[J]. 中华泌尿外科杂志, 2018, 39(4): 275-280. doi: 10.3760/cma.j.issn.1000-6702.2018.04.009 [5] 李欢, 张评梅, 王郁, 等. lncRNA NORAD促进食管鳞状细胞癌EC9706细胞的增殖和迁移[J]. 中国肿瘤生物治疗杂志, 2020, 27(4): 359-364. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202004003.htm [6] SHAO N, TANG H, QU Y Y, et al. Development and validation of lncRNAs-based nomogram for prediction of biochemical recurrence in prostate cancer by bioinformatics analysis[J]. J Cancer, 2019, 10(13): 2927-2934. doi: 10.7150/jca.31132
[7] ZHANG H, MENG H, HUANG X N, et al. lncRNA MIR4435-2HG promotes cancer cell migration and invasion in prostate carcinoma by upregulating TGF-β1[J]. Oncol Lett, 2019, 18(4): 4016-4021.
[8] PRENSNER J R, IYER M K, SAHU A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex[J]. Nat Genet, 2013, 45(11): 1392-1398. doi: 10.1038/ng.2771
[9] 王霞, 姚玉君, 汤静, 等. lncRNA CCAT2对宫颈癌CaSki细胞增殖及周期的影响[J]. 中国肿瘤生物治疗杂志, 2020, 27(6): 640-645. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202006008.htm [10] WU X C, XIAO Y, ZHOU Y, et al. lncRNA SNHG20 promotes prostate cancer migration and invasion via targeting the miR-6516-5p/SCGB2A1 axis[J]. Am J Transl Res, 2019, 11(8): 5162-5169.
[11] BAI T L, LIU Y B, LI B H. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells[J]. IUBMB Life, 2019, 71(10): 1537-1551. doi: 10.1002/iub.2075
[12] SHI Z F, GUO F, JIA D Y, et al. Long non-coding RNA mortal obligate RNA transcript suppresses tumor cell proliferation in prostate carcinoma by inhibiting glucose uptake[J]. Oncol Lett, 2019, 18(4): 3787-3791.
[13] PENG S P, CAO L H, HE S W, et al. An overview of long noncoding RNAs involved in bone regeneration from mesenchymal stem cells[J]. Stem Cells Int, 2018, 2018: 8273648.
[14] LEE R S, ROBERTS C W M. Linking the SWI/SNF complex to prostate cancer[J]. Nat Genet, 2013, 45(11): 1268-1269. doi: 10.1038/ng.2805
[15] PRENSNER J R, ZHAO S, ERHO N, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1[J]. Lancet Oncol, 2014, 15(13): 1469-1480. doi: 10.1016/S1470-2045(14)71113-1
[16] MEHRA R, UDAGER A M, AHEARN T U, et al. Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer[J]. Eur Urol, 2016, 70(4): 549-552. doi: 10.1016/j.eururo.2015.12.003
[17] 李萍, 陈伟, 黄航. LncRNA SChLAP1调节前列腺癌的凋亡作用及其机制研究[J]. 中国现代医生, 2019, 57(16): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS201916008.htm -
期刊类型引用(2)
1. 王向阳. PD-1抑制剂联合SOX方案治疗晚期胃癌患者的疗效及对外周血T淋巴细胞亚群水平的影响. 宁夏医学杂志. 2024(06): 461-464 . 
百度学术
2. 陈守华，姚卫东，徐美华，肖金章，徐薇薇. PD-1单抗和紫杉醇脂质体联合奈达铂一线治疗进展期食管癌的疗效观察. 中国肿瘤临床与康复. 2022(02): 138-141 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 206
- HTML全文浏览量: 94
- PDF下载量: 15
- 被引次数: 2
苏公网安备 32100302010246号
